Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
PR Newswire
January 22, 2022 — 08:00 CST
UNLOCK DATA Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech